Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1585597
Abstract: Introduction The CD6‐CD318 axis has emerged as a potential target for immuno‐oncology. Recent work has shown that blocking the CD6‐CD318 interaction with a murine anti‐human CD6 antibody increases lymphocyte cytotoxicity. However, several studies have demonstrated… read more here.
Keywords: cd318; cytotoxicity; cd6 cd318; cd318 tumor ... See more keywords